Date: Thu, 18 Dec 1997 18:09:24 GMT
Server: Stronghold/1.3.4 Ben-SSL/1.3 Apache/1.1.3
Content-type: text/html
Content-length: 15175
Last-modified: Mon, 06 Oct 1997 14:22:02 GMT

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Questions</TITLE>
<META NAME="Author" CONTENT="Nancy Everett">
<META NAME="Generator" CONTENT="NetObjects Fusion 2.0.1 for Windows">

</HEAD>

<BODY BGCOLOR="#0000FF" LINK="#FFFFFF" VLINK="#FF80C0" TEXT="#FFFFFF">

  <TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=626>
   <TR VALIGN="top" ALIGN="left">
	<TD WIDTH=76 HEIGHT =23><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =76 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=4><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =4 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=421><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =421 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=15><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =15 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=110><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =110 HEIGHT =1 BORDER=0></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD HEIGHT =117></TD>
	<TD WIDTH=440 COLSPAN=3 ALIGN="left" VALIGN="top"><IMG HEIGHT=80 WIDTH=440 SRC="../assets/images/banner1_copy.JPG"  BORDER=0  ALT="Picture" ></TD>
	<TD></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD COLSPAN=2 HEIGHT =2200></TD>
	<TD WIDTH=421><P><B><FONT COLOR="#FFFFFF" SIZE="+2" FACE="ITC Officina Sans Book">frequently asked questions</B></FONT></P><P><B><FONT COLOR="#FF0080" SIZE="+2" FACE="ITC Officina Sans Book">Multikine</B></FONT></P><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Why do you think that Multikine can be successful?</B></FONT></P>
<UL><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Multikine, quite simplistically, is a copy of a healthy person’s immune response.&nbsp; If you believe in the effectiveness of your own immune system, you have to believe that Multikine will help patients whose immune system is weakened by disease.&nbsp; Earlier clinical studies showed rapid tumor responses in terminal cancer patients with no toxic side effects.</FONT></P>
</UL><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Where are you in your clinical studies with Multikine?</B></FONT></P>
<UL><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">We are in phase I/II trials against head and neck cancer in the U.S., Canada and Israel, in phase I against prostate cancer in the U.S., and in phase I against AIDS in the U.S.</FONT></P>
</UL><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">How big is the market for Multikine?</B></FONT></P>
<UL><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Prostate cancer is the number two cancer in men in the U.S. with over 300,000 new cases per year in the U.S. alone.&nbsp; Head and neck cancer has 500,000 annual new cases worldwide.&nbsp; An immune boosting product for AIDS patients should find rapid acceptance among the large number of AIDS patients.&nbsp; In short, there is a substantial market need.</FONT></P>
</UL><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Who are your competitors?</B></FONT></P>
<UL><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">We currently focus on diseases not properly served by the current state of medicine.&nbsp; Multikine, if successful, should have advantages in terms of effectiveness and quality of life.</FONT></P>
</UL><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Where do you manufacture Multikine?</B></FONT></P>
<UL><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">We have built a manufacturing facility and laboratory in Baltimore, Maryland.</FONT></P>
</UL><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Is Multikine patent protected?</B></FONT></P>
<UL><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Yes, it is patent protected.&nbsp; However, equally important is the fact that the manufacture of Multikine is an art form that required us to develop many techniques and tests not previously available.&nbsp; We refer to this as our “Coca-Cola Formula” and like Coca-Cola, we will keep it confidential. </FONT></P>
</UL><P><B><FONT COLOR="#FF0080" SIZE="+2" FACE="ITC Officina Sans Book">HGP-30 AIDS Vaccine</B></FONT></P><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Why do you think that your AIDS vaccine can be successful when so many have already failed?</B></FONT></P>
<UL><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Quite simple!&nbsp; The vaccines that failed almost exclusively focused on parts of the HIV virus which mutate rapidly.&nbsp; As such it is practically impossible to confer protection against next year’s new AIDS strains because you do not know what they will look like.&nbsp; In addition, these vaccines were mostly designed to produce antibodies, which cannot kill the virus infected cells.</FONT></P><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">CEL-SCI, on the other hand, focused on a region of the AIDS virus that is much more constant.&nbsp; Since it will <I>not</I> be much different next year, you can teach the body to recognize future strains and fight them.&nbsp; In addition, CEL-SCI focused on killer T-cells to destroy the virus infected cells, the factories for new virus.</FONT></P>
</UL><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Can you become HIV infected from our vaccine?</B></FONT></P>
<UL><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">No!&nbsp; HGP-30 is an artificial copy of a region of the AIDS virus, not the virus itself.</FONT></P>
</UL><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">What have you seen in your human studies?</B></FONT></P>
<UL><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">HGP-30 has been tested in 39 volunteers not infected with the virus in the U.K. and the U.S.&nbsp; It has also been tested with 24 AIDS infected patients in the U.S.&nbsp; In these studies, HGP-30 has been shown to be safe and to induce the type of immune responses thought to be important in fighting HIV.</FONT></P>
</UL><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Do you have any evidence of protection with HGP-30 against AIDS infection?</B></FONT></P>
<UL><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Yes.&nbsp; CEL-SCI is the only group to have documented substantial protection against a <I>different</I> strain of the HIV virus than the one from which the vaccine was developed.</FONT></P>
</UL><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Where are you in your clinical studies?</B></FONT></P>
<UL><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">We are currently preparing for a phase II study to start in the second half of 1997.&nbsp; Results permitting, we plan to enter into a large phase III HIV prevention study in 1998. This study will be conducted in a third world country that has high levels of HIV infection.&nbsp; Only by going to a country with such high levels of HIV infection can you get a relatively fast answer to the question:&nbsp; <I>“Does the vaccine protect against AIDS infection in a real life setting?”</I>&nbsp; The results of this study may form the basis for a product approval.</FONT></P>
</UL><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Is HGP-30 patent protected?</B></FONT></P>
<UL><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Yes, and more patent applications have been filed during the past year.</FONT></P>
</UL><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Where do you manufacture HGP-30?</B></FONT></P>
<UL><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">HGP-30 is a peptide.&nbsp; There are a multitude of capable contract manufacturers available. Therefore, CEL-SCI does not have a need for its own manufacturing plant right now.</FONT></P>
</UL><P><B><FONT COLOR="#FF0080" SIZE="+2" FACE="ITC Officina Sans Book">L.E.A.P.S. Heteroconjugate</B></FONT></P><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">What does L.E.A.P.S. stand for?</B></FONT></P>
<UL><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book"><U>L</U>igand <U>E</U>pitope <U>A</U>ntigen <U>P</U>resentation <U>S</U>ystem.&nbsp; Early research indicates that it is a system whereby, through the use of a “Ligand” attachment, you can tell the immune system how to process an antigen (e.g. vaccine like HGP-30).&nbsp; This may let you direct the body’s immune system in a way that leads to greater success in fighting or preventing a disease.</FONT></P>
</UL><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Is L.E.A.P.S. patent protected?</B></FONT></P>
<UL><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Yes, and additional applications are anticipated for future products utilizing this technology.</FONT></P>
</UL><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">What diseases are you currently pursuing with L.E.A.P.S.?</B></FONT></P>
<UL><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">Internally we are pursuing HIV in combination with HGP-30, as well as tuberculosis.&nbsp; Externally, we are pursuing malaria with the U.S. Navy and herpes simplex with Northeastern Ohio Universities College of Medicine.&nbsp; These diseases are in dire need of effective treatments and vaccines.&nbsp; If only one of them turns out to lead to a successful product, shareholders should be quite happy.</FONT></P>
</UL><P><B><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">When will L.E.A.P.S. enter into clinical trials?</B></FONT></P><P><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">&nbsp;&nbsp;&nbsp;&nbsp; We hope to have at least one L.E.A.P.S. product in human clinical studies in&nbsp;&nbsp;&nbsp; 1998.</FONT></P><P>&nbsp;</P><P>&nbsp;</TD>

	<TD COLSPAN=2></TD>
   </TR>
  </TABLE>

  <TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=626>
   <TR VALIGN="top" ALIGN="left">
	<TD WIDTH=7 HEIGHT =2><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =7 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=589><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =589 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=30><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =30 HEIGHT =1 BORDER=0></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD></TD>
	<TD WIDTH=589><P><A HREF="../welcome.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Home</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp; </FONT><A HREF="../html/publications.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Publications</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp;&nbsp; </FONT><A HREF="../html/mission.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Mission</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp;&nbsp; </FONT><A HREF="../html/_shareholder_letter.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Shareholder Letter</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp;&nbsp; </FONT><A HREF="../html/product_chart.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Product Chart</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp;&nbsp;&nbsp; </FONT><A HREF="../html/basics.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Basics</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp;&nbsp;&nbsp; </FONT><A HREF="../html/questions.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Questions</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp;&nbsp;&nbsp; </FONT><A HREF="../html/corporate.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Corporate</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp;&nbsp;&nbsp; </FONT><A HREF="../html/investor.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">FY96</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp;&nbsp;&nbsp;&nbsp; </FONT><A HREF="../html/employment.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Employment</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica"></FONT></TD>

	<TD></TD>
   </TR>
  </TABLE>

  <TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=626>
   <TR VALIGN="top" ALIGN="left">
	<TD WIDTH=187 HEIGHT =7><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =187 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=217><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =217 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=222><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =222 HEIGHT =1 BORDER=0></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD HEIGHT =80></TD>
	<TD WIDTH=217><P ALIGN="CENTER"><FONT COLOR="#FFFFFF" SIZE="-1" FACE="Modern">66 Canal Center Plaza Suite 510<BR>&nbsp;Alexandria VA 22314<BR>&nbsp;USA<BR>&nbsp;Telephone: 703-549-5293<BR>&nbsp;Facsimile:&nbsp; 703-549-6269</FONT></TD>

	<TD></TD>
   </TR>
  </TABLE>

  <TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=626>
   <TR VALIGN="top" ALIGN="left">
	<TD WIDTH=224 HEIGHT =19><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =224 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=32><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =32 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=96><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =96 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=39><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =39 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=235><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =235 HEIGHT =1 BORDER=0></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD COLSPAN=2 HEIGHT =44></TD>
	<TD WIDTH=96 ROWSPAN=2>
	  <TABLE BORDER=0 CELLSPACING=0 CELLPADDING=3 >
	 <TR VALIGN="top" ALIGN="left">
		<TD WIDTH=90 HEIGHT=90><A HREF="../welcome.htm"><IMG HEIGHT=90 WIDTH=90 SRC="file:///"  BORDER=0  ALT=" Home " ></A></TD>
	 </TR>
	  </TABLE></TD>
	<TD COLSPAN=2></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD HEIGHT =52></TD>
	<TD WIDTH=167 COLSPAN=3 ROWSPAN=2 BGCOLOR="#000080"><P ALIGN="CENTER"><FONT COLOR="#FFFFFF" SIZE="-1" FACE="Modern">66 Canal Center Plaza Suite 510<BR>&nbsp;Alexandria VA 22314<BR>&nbsp;USA<BR>&nbsp;Telephone: 703-549-5293<BR>&nbsp;Facsimile:&nbsp; 703-549-6269</FONT></TD>

	<TD></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD HEIGHT =38></TD>
	<TD></TD>
   </TR>
  </TABLE>

  <TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=626>
   <TR VALIGN="top" ALIGN="left">
	<TD WIDTH=208 HEIGHT =27><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =208 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=232><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =232 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=186><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =186 HEIGHT =1 BORDER=0></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD HEIGHT =30></TD>
	<TD WIDTH=232><P><A HREF="http://everettcd.com"><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book">site design and hosted by everettcd.com</FONT></A><FONT COLOR="#FFFFFF" SIZE="-1" FACE="ITC Officina Sans Book"></FONT></TD>

	<TD></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD COLSPAN=3 HEIGHT =467></TD>
   </TR>
  </TABLE>
</BODY>
</HTML>
